Evidence map›Paper›PMID 39976324›Full record

ReviewMovement disorders clinical practice2025

Neuroimaging Techniques in Huntington's Disease: A Critical Review.

Mena Farag, Harry Knights, Rachael I Scahill, Peter McColgan, Carlos Estevez-Fraga

Abstract readReview
In one paragraph

Review in Movement disorders clinical practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Review
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Mena FaragHuntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0002-0679-0117
Harry KnightsHuntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Rachael I ScahillHuntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Peter McColganHuntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.
Carlos Estevez-FragaHuntington's Disease Centre, UCL Queen Square Institute of Neurology, University College London, London, United Kingdom.ORCID https://orcid.org/0000-0001-6855-1093

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHuntington's disease (HD) is a hereditary neurodegenerative disorder characterized by cognitive, neuropsychiatric and motor symptoms caused by a CAG trinucleotide repeat expansion in the huntingtin gene. Imaging techniques are crucial for understanding HD pathophysiology and monitoring disease progression.

objectivesThis review is targeted at general neurologists and movement disorders specialists with an interest in HD and aims to bring complex imaging, including new experimental techniques, closer to the practicing clinician.

methodsWe provide a summary of findings from conventional structural, diffusion and functional imaging in HD studies, together with an update on emerging novel techniques, including multiparametric mapping, multi-shell diffusion techniques, ultra-high field 7-Tesla MRI, positron emission tomography and magnetoencephalography.

resultsConventional imaging techniques have deepened our understanding of neuropathological progression in HD, from striatal atrophy to widespread cortical and white matter changes. The integration of novel imaging techniques reviewed has further improved our ability to interrogate, quantify and visualize disease-specific alterations with high precision.

conclusionsNovel imaging techniques have promising roles to further our understanding of HD pathology and as imaging markers for clinical trials, disease staging and therapeutic monitoring. Additionally, the synergistic potential of combining imaging modalities with molecular and genetic data, along with wet biomarkers and clinical data, will help provide a complete and comprehensive view of HD pathology and progression.

Indexed as

BrainHuntington DiseaseNeuroimagingHumansMagnetic Resonance ImagingPositron-Emission Tomography7 T MRIHuntington's diseasemachine learningMEGPET

Identifiers

PMID39976324
PMCPMC12070181

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.